Metro-Minnesota Community Clinical Oncology Program (MM-CCOP)

描述（由申请人提供）：Metro-Minnesota社区临床肿瘤学（MMCCOP）项目有着悠久的历史，从最初的联盟成员的持续承诺和1979年至2014年联盟的发展中可以清楚地看到联盟的成功。MMCCOP联盟代表了一个已建立的社区项目基础，该项目始于1979年，由nci资助的社区医院癌症项目（CHCP）奖。该研究小组于1983年申请并获得了NCI最初的社区临床肿瘤项目（CCOP）资助，并从那时起获得了后续的CCOP资助。2010年，MN ccp项目的医院、诊所和肿瘤学家加入了MMCOP，形成了一个全城市范围的社区癌症研究项目。目前，MMCCOP联盟代表了整个大都市和大明尼苏达地区的21家医院和诊所，采用共同的方法和建立的机制来识别、登记和跟踪nc赞助的治疗、癌症预防、癌症控制和症状管理协议的参与者。mccccp社区的医疗市场仍然极具竞争力，并且由于合并和明尼苏达州的医疗改革举措而不断变化。尽管环境不断变化，MMCCOP医院和相关工作人员继续合作，并支持临床研究试验所涉及的额外时间和费用。在医院内的许多其他项目正在减少或取消的时候，他们的支持水平有所提高。在过去的三十年中，该项目包含了肿瘤社区的大部分成员，并为执业肿瘤学家、医院管理部门和该联盟的其他卫生专业人员之间的交流提供了基础。联合起来，联盟成员平均每年有超过15,000名新的分析性癌症患者。目前，有146名研究人员，分别代表医学、血液学、放射学和外科肿瘤学（包括胸外科和妇科肿瘤学）。MMCCOP研究基地附属机构的历史和扩大NCI赞助研究的积极方法支持了NCI实现和维持这一NCORP倡议目标的能力。MMCCOP打算维持一个区域范围的社区联盟，为社区提供癌症预防、治疗、症状管理和护理提供方面的最新进展。这将通过与alliance、CTSU、ECOG-ACRIN、NRG、MD Anderson、URCC和CCCWFU的持续合作来实现，扩展当前的MMCCOP数据管理和通信系统，以增加研究人员参与累积、项目运营和研究基地活动的数量和水平，实施新战略以改善代表性不足和服务不足群体的访问和参与。并提高专业人士和非专业人士对癌症研究和与MMCCOP合作的好处的认识，以实现NCORP的目标。新的重点将是进一步开发和利用联盟和社区内的专业知识和数据，以提供数据并开展癌症护理交付研究。所有成员机构都是社区肿瘤学项目机构审查委员会的成员，该委员会由Park Nicollet研究所管理，提供有效和及时的研究审查。在过去的5年中，平均有250名患者和400名患者分别参加了nci批准的治疗研究和癌症控制研究。此外，还有1666名参与者参与了积极的跟踪或监视。MMCCCOP已经证明了每年有越来越多的患者进入治疗方案的能力，并提议在该奖项的第一年累计260个治疗研究学分和400个癌症控制和癌症护理提供研究学分，目标是在未来5年内增加癌症护理提供研究的入学人数。这是一个调整良好的研究联盟，有能力在获奖的第一天全面运作。

DESCRIPTION (provided by applicant): The Metro-Minnesota Community Clinical Oncology (MMCCOP) program has a long-standing history which clearly demonstrates the success of the consortium, as demonstrated by both the ongoing commitment of the original consortium members and the growth of the consortium from 1979 through 2014. The MMCCOP consortium represents an established community program base which began in 1979 through its NCI-funded Community Hospital Cancer Program (CHCP) Award. This same consortium applied for and received the initial Community Clinical Oncology Program (CCOP) grant from the NCI in 1983, and has received subsequent CCOP grants since that time. In 2010, hospital, clinics and oncologists in the MN CGOP program joined the MMCOP resulting in a metrowide community cancer research program. Currently, the MMCCOP consortium represents twenty-one hospital and clinics throughout the metropolitan and greater Minnesota area, with a common approach and established mechanisms for identifying, enrolling and following participants on NC-sponsored treatment, cancer prevention, cancer control and symptom management protocols. The health market in the MMCCCP community remains extremely competitive and is in constant change as a result of mergers and Minnesota's healthcare reform initiatives. Despite this changing environment, the MMCCOP hospitals and associated staff continue to collaborate and support the added time and expense involved in clinical research trials. Their level of support has increased during a time when many other projects within the hospitals are being reduced or eliminated. This program incorporates a substantial segment of the oncology community, and has provided a basis for communications between the practicing oncologists, their hospital administrations, and other health professionals in this consortium for the past thiry years. Combined, the consortium members see an average of over 15,000 new analytic cancer patients per year. Currently, there are 146 Investigators, representing medical, hematology, radiation and surgical oncology including thoracic surgery and gynecologic oncology. The history of MMCCOP Research Base Affiliations and proactive approach to expanding access to NCI sponsored studies supports the ability to achieve and maintain the NCI goals for this NCORP initiative. MMCCOP intends to sustain a region wide community consortium which provides the community with the most recent advances in cancer prevention, treatment, symptom management and care delivery. This will be accomplished through continued affiliations with ALL1ANCE,CTSU, ECOG-ACRIN, NRG, MD Anderson, URCC and CCCWFU, the expansion of the current MMCCOP data management and communication system to increase the number and level of participation of the investigators in accrual, program operations and research base activities, implementation of new strategies to improve access and participation of underrepresented and underserved groups, and increase the professional and lay community awareness of the benefits of cancer research and collaboration with the MMCCOP to achieve the goals of the NCORP. A new focus will be to further develop and utilize expertise and data within the consortium and community to provide data and conduct cancer care delivery research. All member institutions are members of the Institutional Review Board for the Community Oncology Programs, administered by Park Nicollet Institute, which provides an efficient and timely review of studies. Over the past 5 years an average of 250 patients and 400 patients were accrued to NCI-approved treatment studies and cancer control studies respectively. Additionally, there are 1666 participants in active follow-up or surveillanc. MMCCCOP has demonstrated the ability to enter an increasing number of patients on protocol each year and proposes to accrue a total of 260 credits to Treatment studies and 400 to Cancer Control and Cancer Care Delivery research studies in the first year of this award with the goal of increasing cancer care delivery research enrollments over the next 5 year. This is a well tuned research consortium with the ability to be fully operational on day one of the award.